- Home
- GWH vs ERNA Comparison
GWH vs ERNA Comparison
Compare GWH & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWH
- ERNA
- Stock Information
- Founded
- GWH 2011
- ERNA 2018
- Country
- GWH United States
- ERNA United States
- Employees
- GWH N/A
- ERNA N/A
- Industry
- GWH Industrial Machinery/Components
- ERNA Biotechnology: Pharmaceutical Preparations
- Sector
- GWH Miscellaneous
- ERNA Health Care
- Exchange
- GWH Nasdaq
- ERNA Nasdaq
- Market Cap
- GWH 61.8M
- ERNA 56.4M
- IPO Year
- GWH N/A
- ERNA N/A
- Fundamental
- Price
- GWH $5.21
- ERNA $0.56
- Analyst Decision
- GWH Buy
- ERNA
- Analyst Count
- GWH 6
- ERNA 0
- Target Price
- GWH $2.54
- ERNA N/A
- AVG Volume (30 Days)
- GWH 122.2K
- ERNA 134.6K
- Earning Date
- GWH 11-13-2024
- ERNA 11-12-2024
- Dividend Yield
- GWH N/A
- ERNA N/A
- EPS Growth
- GWH N/A
- ERNA N/A
- EPS
- GWH N/A
- ERNA N/A
- Revenue
- GWH $6,241,000.00
- ERNA $598,000.00
- Revenue This Year
- GWH $201.33
- ERNA N/A
- Revenue Next Year
- GWH $194.23
- ERNA N/A
- P/E Ratio
- GWH N/A
- ERNA N/A
- Revenue Growth
- GWH 31.11
- ERNA 1072.55
- 52 Week Low
- GWH $4.68
- ERNA $0.52
- 52 Week High
- GWH $20.10
- ERNA $2.63
- Technical
- Relative Strength Index (RSI)
- GWH 35.83
- ERNA 23.08
- Support Level
- GWH $4.68
- ERNA $0.52
- Resistance Level
- GWH $10.12
- ERNA $1.20
- Average True Range (ATR)
- GWH 1.01
- ERNA 0.11
- MACD
- GWH -0.43
- ERNA -0.05
- Stochastic Oscillator
- GWH 9.74
- ERNA 5.53
About GWH ESS Tech Inc.
ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology. The company design and produce long-duration batteries predominantly using earth-abundant materials.
About ERNA Eterna Therapeutics Inc.
Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.